Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis. It is a humanized anti-CD20 monoclonal antibody...

Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis...

approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to...

Research (2020-01-24). "New Drug Therapy Approvals 2019". FDA. "Ocrevus (ocrelizumab) Injection". www.accessdata.fda.gov. Retrieved 2021-07-01. "Search Orphan...

monoclonal treatment, in managing this disease, other anti-CD20 drugs such as ocrelizumab, veltuzumab, and ofatumumab have been explored as potential treatments...

and their approval status: CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab...

deficiency, later discontinued in 2004 and replaced by Nutropin AQ. Ocrevus (ocrelizumab), for MS. Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for...

of generalized myasthenia gravis in the United States in June 2023. Ocrelizumab/hyaluronidase-ocsq (Ocrevus Zunovo) was approved for medical use in the...

in England, Wales and Northern Ireland will be offered injections of ocrelizumab, which can slow the progress of the disease. Princess Anne returns to...

cancer indication due to promising phase II results. 2017: Ocrevus (ocrelizumab): The first FDA-approved therapy that treats both relapsing-remitting...